ProQR Therapeutics (NASDAQ:PRQR) Issues Quarterly Earnings Results

ProQR Therapeutics (NASDAQ:PRQR) released its earnings results on Thursday. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.01, FiscalAI reports. The company had revenue of $5.84 million for the quarter, compared to the consensus estimate of $4.30 million. ProQR Therapeutics had a negative return on equity of 73.83% and a negative net margin of 223.51%.

ProQR Therapeutics Stock Performance

NASDAQ:PRQR traded up $0.12 during midday trading on Thursday, reaching $1.38. 334,152 shares of the stock traded hands, compared to its average volume of 747,607. ProQR Therapeutics has a 12-month low of $1.20 and a 12-month high of $2.48. The business has a 50-day moving average of $1.60 and a two-hundred day moving average of $1.68. The stock has a market capitalization of $144.87 million, a PE ratio of -3.01 and a beta of 0.29.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on PRQR. Bank of America began coverage on shares of ProQR Therapeutics in a research note on Thursday, August 20th. They set a “buy” rating and a $8.00 target price on the stock. Chardan Capital reiterated a “buy” rating and issued a $3.00 price target on shares of ProQR Therapeutics in a research report on Thursday, October 1st. Weiss Ratings raised shares of ProQR Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, August 14th. Citigroup reiterated a “market outperform” rating on shares of ProQR Therapeutics in a research note on Thursday, October 1st. Finally, Wall Street Zen upgraded ProQR Therapeutics from a “strong sell” rating to a “hold” rating in a report on Saturday, August 15th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $7.60.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V. is a biotechnology company focused on developing RNA therapies for genetic diseases. The company uses its Axiomer RNA-editing platform to investigate treatments designed to correct disease-causing genetic changes at the RNA level without permanently altering DNA. ProQR’s research has included therapies for rare inherited disorders, particularly genetic diseases affecting the eye and nervous system. Its development programs have included investigational treatments for inherited retinal diseases, while the company has also pursued partnerships and licensing opportunities to advance RNA-editing applications across additional disease areas.